Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,061 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.
Spencer KR, Portal DE, Aisner J, Stein MN, Malhotra J, Shih W, Chan N, Silk AW, Ganesan S, Goodin S, Gounder M, Lin H, Li J, Cerchio R, Marinaro C, Chen S, Mehnert JM. Spencer KR, et al. Among authors: shih w. Oncotarget. 2023 Apr 10;14:302-315. doi: 10.18632/oncotarget.28403. Oncotarget. 2023. PMID: 37036756 Free PMC article. Clinical Trial.
A phase II trial of riluzole, an antagonist of metabotropic glutamate receptor 1 (GRM1) signaling, in patients with advanced melanoma.
Mehnert JM, Silk AW, Lee JH, Dudek L, Jeong BS, Li J, Schenkel JM, Sadimin E, Kane M, Lin H, Shih WJ, Zloza A, Chen S, Goydos JS. Mehnert JM, et al. Among authors: shih wj. Pigment Cell Melanoma Res. 2018 Jul;31(4):534-540. doi: 10.1111/pcmr.12694. Epub 2018 Apr 10. Pigment Cell Melanoma Res. 2018. PMID: 29453787 Free PMC article. Clinical Trial.
A phase Ib dose-escalation study of troriluzole (BHV-4157), an oral glutamatergic signaling modulator, in combination with nivolumab in patients with advanced solid tumors.
Silk AW, Saraiya B, Groisberg R, Chan N, Spencer K, Girda E, Shih W, Palmeri M, Saunders T, Berman RM, Coric V, Chen S, Zloza A, Vieth J, Mehnert JM, Malhotra J. Silk AW, et al. Among authors: shih w. Eur J Med Res. 2022 Jul 2;27(1):107. doi: 10.1186/s40001-022-00732-w. Eur J Med Res. 2022. PMID: 35780243 Free PMC article. Clinical Trial.
Phase I trial of selenium plus chemotherapy in gynecologic cancers.
Song M, Kumaran MN, Gounder M, Gibbon DG, Nieves-Neira W, Vaidya A, Hellmann M, Kane MP, Buckley B, Shih W, Caffrey PB, Frenkel GD, Rodriguez-Rodriguez L. Song M, et al. Among authors: shih w. Gynecol Oncol. 2018 Sep;150(3):478-486. doi: 10.1016/j.ygyno.2018.07.001. Epub 2018 Jul 29. Gynecol Oncol. 2018. PMID: 30068487 Free PMC article. Clinical Trial.
Phase I neoadjuvant study of intravesical recombinant fowlpox-GM-CSF (rF-GM-CSF) or fowlpox-TRICOM (rF-TRICOM) in patients with bladder carcinoma.
Portal DE, Weiss RE, Wojtowicz M, Mansour A, Monken C, Mehnert JM, Aisner JA, Kane M, Nishioka J, Aisner S, Peters S, Stein MN, Kim IY, Mayer TM, Shih W, Gulley J, Streicher H, Singer EA, Lattime EC. Portal DE, et al. Among authors: shih w. Cancer Gene Ther. 2020 Jun;27(6):438-447. doi: 10.1038/s41417-019-0112-z. Epub 2019 Jun 20. Cancer Gene Ther. 2020. PMID: 31222182 Free PMC article. Clinical Trial.
High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma.
Silk AW, Kaufman HL, Curti B, Mehnert JM, Margolin K, McDermott D, Clark J, Newman J, Bommareddy PK, Denzin L, Najmi S, Haider A, Shih W, Kane MP, Zloza A. Silk AW, et al. Among authors: shih w. Front Oncol. 2020 Jan 10;9:1483. doi: 10.3389/fonc.2019.01483. eCollection 2019. Front Oncol. 2020. PMID: 31998643 Free PMC article.
1,061 results